ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Ultrasound-Responsive Dual-Prodrug Nanoassembly for "Fenestrae-Restoration Strategy" in Liver Fibrosis Therapy.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver sinusoidal endothelial cell fenestrations in metabolic liver disease: from molecular mechanisms to therapeutic perspectives.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Liver fibrosis is a serious yet reversible intermediate stage in the progression of liver disease, which can ultimately advance to cirrhosis and hepatocellular carcinoma. Targeted and selective inhibition of activated hepatic stellate cells (aHSCs) has emerged as a promising therapeutic strategy for the treatment of liver fibrosis. However, the capillarization of liver sinusoidal endothelial cells (LSECs) characterized by the loss of fenestrae and continuous formation of basement membrane presents a significant barrier to effective delivery of anti-fibrotic agents. In this study, we propose a novel "fenestrae-restoration strategy" employing ultrasound-responsive polymeric dual prodrug nanoassembly (PMS) co-loaded with nitric oxide prodrug (mSNO) and poly-metformin (PMet). PMS is engineered for controllable, ultrasound-triggered release of nitric oxide from mSNO, which activates soluble guanylate cyclase. This results in upregulation of intracellular cyclic guanosine monophosphate that facilitates the reversal of LSECs capillarization, restoring fenestrae and enhancing endothelial permeability. This restoration enables PMS to traverse the hepatic sinusoidal barrier, followed by accumulation in fibrotic tissue, where PMet is internalized by aHSCs. In lysosomes, metformin released from PMet ultimately inhibits aHSCs proliferation and migration via the AMPK-mTOR pathway deregulation. The therapeutic efficacy and underlying mechanisms of "fenestrae-restoring strategy" were comprehensively validated in preclinical CCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.